He discusses the positioning of JAK inhibitors in the treatment of inflammatory bowel disease, which he presented at the virtual AIBD regional meeting July 25.
Three researchers from the Wolfson Institute for Preventative Medicine, Queen Mary University and The London Hospital offered the argument for just that in the British Journal of Medicine.